N/A N=40 Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing
HIV Infections · Alcohol Abuse
Primary: Number of New Sex Partners, Past 30 Days — 2.53; 1.37 New partners
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=270 Brain Mechanisms of Human Motivation
Major Depressive Disorder · Bipolar Disorder
Primary: Change in Response Bias — .0546; .0787 log-transformed ratio of scores
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 2 N=427 A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%) at Week 20 Measured by Echocardiography — -2.19; 2.59; -3.01; 0.13 Percentage of LVEF…
Phase 3 N=431 A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
Plaque Type Psorisis
Primary: Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set) — 80.4; 81.7 percentage of participants
Phase 2 N=41 Calcitriol, Physical Activity, and Bone Health in Cancer Survivors
Breast Neoplasms · Bone and Bones
Primary: Bone Resorption (Exercise) — 13.8; 14.7 nm BCE — p=0.86
Phase 3 N=387 A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Melanoma
Primary: The Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events (AEs) — 32.8; 45.5 Percentage of participants — p=0.0144
Phase 3 N=129 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Subjects With Hyperlipidemia, Dyslipidemia
Primary: Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16 — -5.31; -8.31 percent change — p=0.18
Phase 3 N=698 Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16 — -2.64; -3.23; -3.37 units on a scale — p=0.0129
Phase 3 N=151 Prevention of Post-operative Urinary Retention
Urinary Retention · Urinary Tract Infections
Primary: Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome — 18; 22 Participants
Phase 2 N=34 Eltrombopag for Moderate Aplastic Anemia
Moderate Aplastic Anemia · Unilineage Bone Marrow Failure Disorders
Primary: Proportion of Drug Responders — 17 Participants
Phase 4 N=66 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Atrial Fibrillation
Primary: Coronary Artery Calcium (CAC) Score — 66; 31 units on a scale
Phase 2 N=30 Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome
Pain
Primary: Count/Percentage of Patients Who Report Having Experienced the Paclitaxel-induced Pain Syndrome (PIAPS) for One Week After Paclitaxel After Enrollment to the Current…
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Phase 3 N=30 A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
Epilepsy
Primary: Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs — 23; 5 Participants